Lif and SwedenBIO welcomes the opportunity to be a part of the creation of the Biotech Act and strongly support the intent to foster an innovation-conducive framework to improve the competitiveness of the EU biopharmaceutical sector. At the light of the geopolitical reality the EU now faces, ongoing and future regulation must ensure innovation and competitiveness without imposing additional regulatory burdens.
LRB
Lif – the research-based pharmaceutical industry
Industry association · Sweden · EU Transparency Register 544344129150-31
5
positions filed
in the 326 files tracked
5
legislative files
of 326 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1205 trade and business associations on this site, they rank #335 by legislative files engaged — a count of participation, not a measure of influence.
2
declared lobbying FTE
self-declared
€50K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2017
in the register since
Declares membership of
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Trade and business associations
- Registered as
- Läkemedelsindustriföreningen (Lif)
- Head office
- Stockholm, Sweden
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Lif in PolicySpeak: request access →
Work at Lif – the research-based pharmaceutical industry? so we know who speaks for it.
Their record over time
Lif – the research-based pharmaceutical industry filed 5 positions between 22 May 2025 and 3 Oct 2025, across 5 of the 326 legislative files tracked here, attaching a full position paper 2 times.
What they argued
Lif the research-based pharmaceuticals industry in Sweden is grateful for the opportunity to give our remarks on the proposed regulation. The pharmaceutical industry in Sweden is of great strategic importance. Employing over 16,000 people, its total exports of pharmaceuticals from Sweden amount to SEK 151 billion. Swedish and European companies in this sector invest heavily in research and development.
Lif representing nearly 100 innovative pharmaceutical companies in Sweden welcomes the European Commissions initiative to develop a coherent and future-proof EU strategy on research and technology infrastructures.
Lif the research-based pharmaceuticals industry in Sweden is grateful for the opportunity to give our remarks on the proposed regulation and directive with the goal of aligning product legislation with the digital age. The life sciences sectorcovering pharmaceuticals, medical devices, in vitro diagnostics, medical software, and biotechnologyis a strategic industry for Sweden.
Lif the research-based pharmaceuticals industry in Sweden is grateful for the opportunity to give our remarks on the proposed regulation and directive with the goal of aligning product legislation with the digital age. The life sciences sectorcovering pharmaceuticals, medical devices, in vitro diagnostics, medical software, and biotechnologyis a strategic industry for Sweden.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- Wirtschaftskammer Österreich · 3 files in common
- EDF - Electricité de France · 3 files in common
- DIGITALEUROPE · 3 files in common
- EuroCommerce · 3 files in common
- Danish Industry · 3 files in common
Showing 5 of 104.
Is this your organization?
Everything on this page comes from Lif – the research-based pharmaceutical industry’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.